Regeneron director Zoghbi proposes $7.22M share sale

The proposed sale is listed at an aggregate market value of $7,219,262.83, alongside 101,630,713 common shares outstanding.

Available on EDGAR 11/03/2026 - 04:15 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. (REGN) director Huda Zoghbi filed a notice covering the proposed sale of 7,439 common shares, with an approximate sale date of November 3, 2026. The notice lists a stock option exercise from the company for cash as the acquisition transaction and identifies NASDAQ as the exchange. It also reports that Zoghbi sold 800 shares on August 10, 2026, for $640,000 during the preceding three months.

Key Figures

Proposed sale: 7,439 common shares Aggregate market value: $7,219,262.83 Common shares outstanding: 101,630,713 shares +2 more

5 metrics

Proposed sale 7,439 common shares Approximate sale date: November 3, 2026

Aggregate market value $7,219,262.83 Proposed sale

Common shares outstanding 101,630,713 shares Stated with the proposed sale details

Prior shares sold 800 shares August 10, 2026

Aggregate market value of prior shares sold $640,000 Shares sold August 10, 2026

Key Terms

Rule 144, stock option exercise

2 terms

Rule 144 regulatory

"sales required by paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"stock option exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares does Huda Zoghbi plan to sell?

Huda Zoghbi's notice covers a proposed sale of 7,439 REGN common shares. The approximate sale date is November 3, 2026, the stated aggregate market value is $7,219,262.83, and NASDAQ is listed as the exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001681643
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Regeneron Pharmaceuticals, Inc.
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill River Road Tarrytown NEW YORK 10591
Phone	914-847-7000
Name of Person for Whose Account the Securities are To Be Sold	Huda Zoghbi
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	7439	7219262.83	101630713	11/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common stock	11/03/2026	stock option exercise	company			7439	11/03/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Huda Zoghbi 777 Old Saw Mill River Road Tarrytown NY 10591	common stock	08/10/2026	800	640000

144: Remarks and Signature

Remarks
Date of Notice	11/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Mijo Suric, for UBS Financial Services Inc, as attorney-in-fact for Huda Zoghbi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)